← Eichor
Study identifier: NCT05965284 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Condition: ANCA-associated Vasculitis · Maintenance Therapy  ·  Sponsor: Chinese SLE Treatment And Research Group

PhasePhase 4
Planned participants40
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with Telitacicept combined with azathioprine and azathioprine alone in remission-maintenance treatment of AAV.

This description comes directly from the study's public registry record.

Talk to the study team

Yunjiao Yang, M.D.  ·  +86-13671313079  ·  yangyunjiao81@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05965284